Healthcare / BiotechnologyHKSE
$0.39
-0.02 (-3.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 17%
FCF escenarios
weak_data · normalized FCF $10.5M · quality 35.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$117M
P/E
4.3x
↓EV/EBITDA
6.1x
↓ROE
51.5%
↑Gross Margin
58.2%
↑Debt/Equity
0.96
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+20.2%
FCF CAGR
—
FCF margin
5.6%
FCF / Net income
0.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $72.1M · net income $27.5M · FCF $4.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $72.1M | $72.1M | $90.6M | $69.5M | $41.5M |
| Net Income | $27.5M | $27.5M | $17.8M | $-107.7M | $4.6M |
| EBITDA | $26.2M | $26.2M | $29.8M | $-95.4M | $14.4M |
| EPS | 0.09 | 0.09 | 0.06 | -0.38 | 0.02 |
| Gross Margin | 58.2% | 58.2% | 63.6% | 28.0% | 90.6% |
| Operating Margin | -2.2% | -2.2% | 20.4% | -157.0% | 29.6% |
| Net Margin | 38.2% | 38.2% | 19.6% | -155.0% | 11.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.96 | 0.96 | 2.13 | 4.26 | 0.69 |
| Current Ratio | 1.14 | 1.14 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $4.0M | $4.0M | $17.7M | $10.5M | $-15.0M |
| Returns | |||||
| ROE | 51.5% | 51.5% | 70.5% | -913.2% | 4.4% |
| Valuation | |||||
| P/E | 4.28 | 4.28 | 5.15 | — | 69.38 |
| EV/EBITDA | 6.11 | 6.11 | 4.10 | — | 26.80 |
| P/B | 2.19 | 2.19 | 3.62 | 13.36 | 3.05 |
| Growth & Yield | |||||
| Revenue Growth | -20.5% | -20.5% | 30.4% | 67.3% | — |
| EPS Growth | 55.2% | 55.2% | 115.5% | -2450.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-27.7%
EPS terminal req.
$0.03
Spread vs growth
83.0%
5Y implied EPS CAGR
-14.5%
EPS terminal req.
$0.04
Spread vs growth
69.7%
10Y implied EPS CAGR
-3.0%
EPS terminal req.
$0.07
Spread vs growth
58.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+24.2%
Start / end P/E
5.3x → 4.3x
EPS bridge
0.06 → 0.09
Residual
-11.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.